Valneva and LimmaTech Secure FDA Fast Track Designation
Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a leader in specialty vaccines, and LimmaTech Biologics AG, a developer of vital biotech solutions, celebrate a significant milestone. They announced that their tetravalent bioconjugate Shigella vaccine candidate S4V has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). This designation accelerates the process for critical products aiming to address serious health conditions and unmet medical needs.
Understanding Fast Track Designation
Fast Track designation is a crucial FDA initiative aimed at facilitating the development of treatments for serious diseases and expedites the review of these essential new therapies. This program aims to streamline the pathway to getting vital treatments into the hands of those who need them most as quickly as possible.
CEO Insights
Thomas Lingelbach, the Chief Executive Officer of Valneva, highlighted the urgency of addressing shigellosis, a leading cause of fatal diarrhea globally, noting, "Currently, there is no approved Shigella vaccine. The Fast Track designation allows us to closely collaborate with the FDA to expedite our progress in developing remedies for this devastating disease."
Partnerships and Development Plans
The partnership between Valneva and LimmaTech includes an exclusive licensing agreement for the S4V candidate, further asserting their commitment to combat this health threat. Following favorable results from earlier clinical trials, Valneva is prepared to advance into Phase 2 studies that will investigate the vaccine's efficacy, especially among high-risk populations.
Shigellosis and its Global Impact
Shigellosis poses a significant public health challenge, particularly in low- and middle-income countries (LMICs) where it's estimated that there are about 165 million cases annually. This illness accounts for approximately 600,000 deaths each year, primarily affecting children under five years old. As international travel increases, the risk also extends to individuals from wealthier nations and military personnel deployed in endemic areas.
The Need for an Effective Vaccine
Despite the critical need, there are currently no licensed vaccines for Shigella, which complicates management and treatment. The standard approaches of oral rehydration and antibiotics face challenges due to rising antibiotic resistance, making the development of new preventive solutions imperative.
Future Directions
Valneva's S4V has a promising path ahead, leveraging a combination of Controlled Human Infection Model studies for initial approval in adults. The plan includes expanding indications for pediatric populations, thereby addressing a broader segment of the community affected by shigellosis. The targeted approach to development signals significant potential for comprehensive health solutions.
Company Profiles
Valneva SE is dedicated to the innovative development of vaccines, focusing on unmet needs for infectious diseases. Their extensive portfolio includes the world’s first and only chikungunya vaccine, among others. Their commitment to advancing significant health solutions is underscored by a strong R&D pipeline.
LimmaTech Biologics AG is recognized for its pioneering work in tackling the global antimicrobial resistance crisis. Their advanced vaccine technologies and strategic approaches aim to create impactful solutions for infectious diseases, revealing a commitment to global health.
Contact Information
Valneva Investor & Media Contacts
Laetitia Bachelot-Fontaine, VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com
Joshua Drumm, Ph.D., VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
Media Enquiries
Trophic Communications
Gretchen Schweitzer or Alison Opalko
Phone: +49 172 861 8540
E-mail: limmatech@trophic.eu
Frequently Asked Questions
What is the significance of Fast Track designation?
Fast Track designation expedites the clinical development and review of treatments addressing serious diseases, aiming to deliver solutions to patients sooner.
Why is the S4V vaccine important for public health?
Shigellosis causes significant morbidity and mortality worldwide, especially among children. The S4V vaccine aims to fill the gap by providing preventive solutions.
What are the next steps for the S4V vaccine's development?
The S4V vaccine will undergo Phase 2 studies to evaluate its efficacy and expand its usage to children, enhancing public health measures against shigellosis.
How does Valneva contribute to vaccine innovation?
Valneva specializes in developing vaccines for infectious diseases that meet unmet medical needs, using innovative methodologies to advance their vaccine pipeline.
Who are the key players behind the S4V vaccine?
The S4V vaccine is a collaborative effort between Valneva SE and LimmaTech Biologics AG, focusing on innovative solutions for preventing shigellosis.
